BioSpace News Archive

Business

Mettler-Toledo International Reports Fourth Quarter 2017 Results

Sales in local currency increased 6% in the quarter compared with the prior year.

February 8, 2018
·
41 min read
FDA

QIAGEN’s QuantiFERON-TB Gold Plus Gains Approval in Japan

QIAGEN N.V. today announced that Japan’s Ministry of Health Labor and Welfare has approved QuantiFERON-TB Gold Plus (QFT-Plus) as an in vitro diagnostic to detect tuberculosis (TB) infection.

February 8, 2018
·
1 min read
Business

Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results

Income from operations for the fourth quarter of 2017 was $66.4 million, compared with $37.7 million for the same period in 2016.

February 8, 2018
·
16 min read
Biotech Bay

Adverum Biotechnologies Announces Pricing of $60M Public Offering of Common Stock

Adverum Biotechnologies today announced the pricing of an underwritten public offering of 8,888,900 shares of its common stock at a price to the public of $6.75 per share.

February 8, 2018
·
3 min read
Drug Development

Amgen Release: Results From Phase III XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology

In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85-1.14).

February 8, 2018
·
18 min read
Genetown

Sage Therapeutics Prices Public Offering of 3,506,098 Shares of its Common Stock

The gross proceeds to Sage Therapeutics from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $575.0 million.

February 8, 2018
·
5 min read